Park Avenue Securities LLC Invests $358,000 in Hims & Hers Health, Inc. $HIMS

Key Points

• Park Avenue Securities LLC has invested approximately $358,000 in Hims & Hers Health, acquiring 7,181 shares of the company during the second quarter.
• Shares of Hims & Hers Health fell by 4.1% recently, with stock trading between a 12-month low of $16.05 and a high of $72.98.
• Despite a 72.6% year-over-year revenue growth, the company reported an earnings per share of $0.17, which was below analysts' expectations of $0.18.

Park Avenue Securities LLC bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 7,181 shares of the company's stock, valued at approximately $358,000.

A number of other institutional investors also recently modified their holdings of HIMS. Public Employees Retirement System of Ohio purchased a new stake in shares of Hims & Hers Health in the 4th quarter worth about $99,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Hims & Hers Health in the 4th quarter worth about $213,000. California State Teachers Retirement System lifted its position in shares of Hims & Hers Health by 18.8% in the 4th quarter. California State Teachers Retirement System now owns 166,337 shares of the company's stock worth $4,022,000 after purchasing an additional 26,363 shares during the period. GAMMA Investing LLC lifted its position in shares of Hims & Hers Health by 6,651.5% in the 1st quarter. GAMMA Investing LLC now owns 151,976 shares of the company's stock worth $44,910,000 after purchasing an additional 149,725 shares during the period. Finally, Rhumbline Advisers lifted its position in shares of Hims & Hers Health by 15.7% in the 1st quarter. Rhumbline Advisers now owns 597,331 shares of the company's stock worth $17,651,000 after purchasing an additional 81,107 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Down 4.1%

Shares of HIMS stock opened at $56.71 on Wednesday. Hims & Hers Health, Inc. has a 12 month low of $16.05 and a 12 month high of $72.98. The stock has a market cap of $12.82 billion, a P/E ratio of 70.89, a P/E/G ratio of 3.99 and a beta of 2.14. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. The company has a 50 day simple moving average of $51.59 and a two-hundred day simple moving average of $46.79.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million for the quarter, compared to analysts' expectations of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm's quarterly revenue was up 72.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 60,000 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total value of $3,214,800.00. Following the completion of the transaction, the insider directly owned 169,940 shares in the company, valued at $9,105,385.20. This represents a 26.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 660,000 shares of the company's stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the completion of the transaction, the chief executive officer owned 2,214,769 shares of the company's stock, valued at approximately $112,023,016.02. The trade was a 22.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,622,727 shares of company stock worth $83,566,691 over the last three months. 17.71% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on HIMS shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Zacks Research cut shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Wall Street Zen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Monday, July 28th. Canaccord Genuity Group reissued a "buy" rating and set a $68.00 price target on shares of Hims & Hers Health in a research report on Friday, September 12th. Finally, Morgan Stanley restated an "equal weight" rating and set a $40.00 price target on shares of Hims & Hers Health in a report on Wednesday, June 11th. Two research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat, Hims & Hers Health has an average rating of "Reduce" and an average price target of $38.92.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.